The Current Best-Selling Drug in the World Drives AbbVie's Q1 Profit Higher by 4%

Global pharmaceutical giant AbbVie (NYSE: ABBV  ) reported another quarter of steady growth in Q1 this morning, with the current best-selling drug in the world, Humira, once again leading the way.

For the quarter, AbbVie reported revenue of $4.56 billion, a 5.4% increase from the year-ago period and inclusive of a negative 1.3% effect from currency translation. Humira, the company's rheumatoid arthritis blockbuster, delivered 17.5% worldwide sales growth to $2.64 billion for the quarter, putting it on pace for more than $10 billion in annual sales. U.S. sales provided much of the spark with revenue domestically up 24.7%.

Also boosting AbbVie's topline was low testosterone therapy AndroGel, which grew sales by 6% to $254 million; hypothyroidism drug Synthroid, whose sales jumped an impressive 31.5% to $157 million; and Creon, an exocrine pancreatic insufficiency medication, which delivered an 18.4% increase in sales to $107 million.

Profit for the quarter improved by a modest 4.4% to an adjusted $0.71 per share, largely due to Humira's higher sales, but partially offset by higher research and development, as well as selling, general and administrative expenses. Nonetheless, adjusted gross margin expanded 220 basis points to 78.4%.

Looking forward, AbbVie reaffirmed its previously issued full-year guidance which calls for $3-$3.10 in adjusted EPS on revenue of approximately $19 billion. This forecast excludes any potential revenue benefit it could receive from its direct-acting antiviral candidate for hepatitis C were it to be approved and hit pharmacy shelves before the year is out. AbbVie submitted the new drug application for its DAA HCV drug earlier this week.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2930546, ~/Articles/ArticleHandler.aspx, 8/28/2015 8:28:45 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:04 PM
ABBV $63.98 Down -0.53 -0.82%
AbbVie Inc. CAPS Rating: ****